全文获取类型
收费全文 | 379146篇 |
免费 | 24728篇 |
国内免费 | 1529篇 |
专业分类
耳鼻咽喉 | 4174篇 |
儿科学 | 9618篇 |
妇产科学 | 6838篇 |
基础医学 | 48476篇 |
口腔科学 | 7519篇 |
临床医学 | 38206篇 |
内科学 | 79649篇 |
皮肤病学 | 6225篇 |
神经病学 | 36965篇 |
特种医学 | 16207篇 |
外国民族医学 | 27篇 |
外科学 | 59742篇 |
综合类 | 4376篇 |
现状与发展 | 1篇 |
一般理论 | 281篇 |
预防医学 | 27603篇 |
眼科学 | 8611篇 |
药学 | 24698篇 |
1篇 | |
中国医学 | 542篇 |
肿瘤学 | 25644篇 |
出版年
2023年 | 2104篇 |
2022年 | 3511篇 |
2021年 | 8320篇 |
2020年 | 4907篇 |
2019年 | 7811篇 |
2018年 | 9237篇 |
2017年 | 6989篇 |
2016年 | 7651篇 |
2015年 | 8919篇 |
2014年 | 12851篇 |
2013年 | 17474篇 |
2012年 | 26490篇 |
2011年 | 27854篇 |
2010年 | 15752篇 |
2009年 | 14721篇 |
2008年 | 24505篇 |
2007年 | 25739篇 |
2006年 | 25259篇 |
2005年 | 25146篇 |
2004年 | 23452篇 |
2003年 | 21567篇 |
2002年 | 20644篇 |
2001年 | 3955篇 |
2000年 | 3177篇 |
1999年 | 4006篇 |
1998年 | 4540篇 |
1997年 | 3624篇 |
1996年 | 3157篇 |
1995年 | 2915篇 |
1994年 | 2558篇 |
1993年 | 2436篇 |
1992年 | 2227篇 |
1991年 | 2082篇 |
1990年 | 1783篇 |
1989年 | 1691篇 |
1988年 | 1561篇 |
1987年 | 1472篇 |
1986年 | 1494篇 |
1985年 | 1522篇 |
1984年 | 1809篇 |
1983年 | 1559篇 |
1982年 | 1937篇 |
1981年 | 1793篇 |
1980年 | 1538篇 |
1979年 | 1110篇 |
1978年 | 1138篇 |
1977年 | 970篇 |
1976年 | 921篇 |
1975年 | 735篇 |
1974年 | 814篇 |
排序方式: 共有10000条查询结果,搜索用时 1 毫秒
101.
102.
103.
The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres. 总被引:5,自引:0,他引:5
Gayle Duncan Thomas J Jess Farahidah Mohamed Nicholas C Price Sharon M Kelly Christopher F van der Walle 《Journal of controlled release》2005,110(1):34-48
Encapsulation of proteins in poly(lactide-co-glycolide) microspheres via emulsion is known to cause insoluble protein aggregates. Following protein emulsification and encapsulation in PLGA microspheres, we used circular dichroism to show that the recoverable soluble protein fraction also suffers subtle conformational changes. For a panel of proteins selected on the basis of molecular size and structural class, conformational stability measured by chemical denaturation was not indicative of stability during emulsion-encapsulation. Partial loss of structure was observed for alpha-helical proteins released from freeze-dried microspheres in aqueous buffer, with dramatic loss of structure for a beta-sandwich protein. The addition of sucrose (a lyoprotectant) did not prevent the loss of protein conformation upon encapsulation. Therefore, the conformational changes seen for the released soluble protein fraction originates during emulsification rather than microsphere freeze-drying. Analysis of the burst release for all proteins in buffer containing denaturant or surfactant showed that the degree of protein solubilisation was the dominant factor in determining the initial rate and extent of release. Our data for protein release into increasing concentrations of denaturing buffer suggest that the emulsion-denatured protein fraction remains insoluble; this fraction may represent the protein loss encountered upon comparison of protein encapsulated versus protein released. 相似文献
104.
Treatment of thrombocytopenia with alfa interferon 总被引:1,自引:0,他引:1
A M Lever M G Brook I Yap H C Thomas 《British medical journal (Clinical research ed.)》1987,295(6612):1519-1520
105.
106.
Trawat Attarbaschi Julia Sacher Thomas Geiss-Granadia Nikolas Klein Nilufar Mossaheb Rupert Lanzenberger Susanne Asenbaum Robert Dudczak Siegfried Kasper Johannes Tauscher 《European neuropsychopharmacology》2007,17(2):102-107
We explored the relationship between striatal dopamine-2 (D(2)) receptor occupancy and extra-pyramidal symptoms (EPS) in bipolar patients receiving olanzapine. Seventeen patients with a DSM-IV diagnosis of bipolar disorder were treated with 5-45 mg/day olanzapine for at least 14 days. After that period, D(2) receptor occupancy was determined using Iodobenzamide (IBZM) and SPECT. EPS were assessed by the Simpson-Angus Scale (SAS) and Barnes-Akathisia Scale (BAS). We found a dose-dependent increase in occupancy: 5 mg led to 28-50%, 10 mg to 40-68%, 15 mg to 69%, 20 mg to 57-66%, 30 mg to 66% and 45 mg to 80% D(2) receptor occupancy; and a significant correlation between plasma levels and occupancy (R(2)=.55, P=.001). Similar to schizophrenic patients, bipolar patients did not exhibit EPS at D(2) occupancy levels of 28 to 80%. Although we did not find an increased vulnerability for acute EPS in bipolar patients receiving olanzapine at clinical relevant doses, this needs to be replicated with larger sample sizes. 相似文献
107.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
108.
Regula E Egli Thomas L Kash Kevin Choo Valentina Savchenko Robert T Matthews Randy D Blakely Danny G Winder 《Neuropsychopharmacology》2005,30(4):657-668
The bed nucleus of the stria terminalis (BNST) and its adrenergic input are key components in stress-induced reinstatement and maintenance of drug use. Intra-BNST injections of either beta-adrenergic receptor (beta-AR) antagonists or alpha2-adrenergic receptor (alpha2-AR) agonists can inhibit footshock-induced reinstatement and maintenance of cocaine- and morphine-seeking. Using electrophysiological recording methods in an in vitro slice preparation from C57/Bl6j adult male mouse BNST, we have examined the effects of adrenergic receptor activation on excitatory synaptic transmission in the lateral dorsal supracommissural BNST (dBNST) and subcommissural BNST (vBNST). Alpha2-AR activation via UK-14,304 (10 microM) results in a decrease in excitatory transmission in both dBNST and vBNST, an effect predominantly dependent upon the alpha2A-AR subtype. Beta-AR activation via isoproterenol (1 microM) results in an increase in excitatory transmission in dBNST, but not in vBNST. Consistent with the work with receptor subtype specific agonists, application of the endogenous ligand norepinephrine (NE, 100 microM) elicits two distinct effects on glutamatergic transmission. In dBNST, NE elicits an increase in transmission (62% of dBNST NE experiments) or a decrease in transmission (38% of dBNST NE experiments). In vBNST, NE elicits a decrease in transmission in 100% of the experiments. In dBNST, the NE-induced increase in synaptic transmission is blocked by beta1/beta2- and beta2-, but not beta1-specific antagonists. In addition, this increase is also reduced by the alpha2-AR antagonist yohimbine and is absent in the alpha2A-AR knockout mouse. In vBNST, the NE-induced decrease in synaptic transmission is markedly reduced in the alpha2A-AR knockout mouse. Further experiments demonstrate that the actions of NE on glutamatergic transmission can be correlated with beta-AR function. 相似文献
109.
110.
Michael R Horsman 《International journal of hyperthermia》2006,22(3):197-203
The most important physiological parameter influencing tissue response to heat is blood flow. At mild hyperthermia temperatures blood perfusion increases in many tumours and this effect is heating time-, temperature- and tumour-dependent. These flow increases can improve tumour oxygenation. When heating is terminated, perfusion and oxygenation commonly recover, although how quickly this occurs appears to be tumour-specific. While these effects are unlikely to have any anti-tumour activity they can be exploited to improve the combination of heat with other therapies. However, since similar physiological effects should occur in normal tissues, such combination therapies must be carefully applied. Heating tumours to higher temperatures typically causes a transient increase in perfusion during heating, followed by vascular collapse which if sufficient will increase tumour necrosis. The speed and degree of vascular collapse is dependent on heating time, temperature and tumour model used. Such vascular collapse generally occurs at temperatures that cause a substantial blood flow increase in certain normal tissues, thus preferential anti-tumour effects can be achieved. The tumour vascular supply can also be exploited to improve the response to heat. Decreasing blood flow, using transient physiological modifiers or longer acting vascular disrupting agents prior to the initiation of heating, can both increase the accumulation of physical heat in the tumour, as well as increase heat sensitivity by changing the tumour micro-environmental parameters, primarily an increase in tumour acidity. Such changes are generally not seen in normal tissues, thus resulting in a therapeutic benefit. 相似文献